BackZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) Overview

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) Current Cash

Track ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s current cash ($300M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$302.66M
↓ 81.22% YoYΔ $-1.31B vs prior year quarter

Peer average

Loading

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) Current Cash History

Loading

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) vs. peers: Current Cash Comparison

Loading

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) (LSPRU) FAQ

As of the most recent data (March 2026), LSPRU shows a current cash of $300M. That compares with $1.6B in the prior-year period — down 81.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LSPRU's current cash is now $300M (was $1.6B) — a 81.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) is outperforming or lagging.

Tracking LSPRU's current cash over time shows whether ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) is scaling, shrinking, or reshaping that part of the business. The current reading is $300M That compares with $1.6B in the prior-year period — down 81.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $300M) with ownership activity and broader fundamentals.